Our results expand on this work demonstrating that the stimulation using EGFRvIII-DBTE can induce CD4+ T cells to participate directly to kill target GBM and likely can be an important tool to recruit effector CD4+ T cells to target these tumors. Here, CD4 is linked to glioblastoma.